Pear Bio

Executive Summary

Pear Bio is a UK-based biotechnology company pioneering functional precision medicine for hard-to-treat cancers. Founded in 2019, the company develops personalized diagnostic tests by creating 3D immune-microtumors from patient biopsies. These microtumors, which incorporate the patient's own immune cells, are used to predict treatment response to various therapies. Additionally, Pear Bio leverages excess biopsy tissue for multi-omic analysis to identify novel therapeutic targets and accelerate drug development. The platform addresses a critical unmet need in oncology, where standard molecular profiling often fails to predict clinical outcomes, especially in complex and resistant tumors. By providing a functional readout of tumor-immune interactions, Pear Bio's test could guide treatment decisions for patients with limited options, potentially improving response rates and survival. Pear Bio operates in the rapidly growing precision oncology market, with potential applications across multiple solid tumor types. The company's approach combines organoid technology with immune co-culture, a differentiated offering compared to pure genomic tests. While still in early stages—with no disclosed funding or clinical data—the platform has the potential to attract strategic partnerships with pharmaceutical companies seeking to optimize clinical trial design or identify biomarker-driven patient populations. Pear Bio's dual focus on diagnostics and therapeutics discovery positions it well for future growth. However, validation through clinical studies and regulatory clearance will be critical for adoption. With a novel technology and a strong scientific foundation, Pear Bio represents an intriguing opportunity in the functional precision medicine space.

Upcoming Catalysts (preview)

• Q4 2026Clinical validation study results60% success
• Q2 2027Strategic partnership with a pharmaceutical company50% success
• Q3 2026Series A funding round55% success